相关数据集
"Rethinking Immunogenicity: An Integrated Approach Reveals the PK/PD Impact of Pre-existing and Drug-Sustaining ADA" Supplemental Materials-PK parameters Tables 1 and 2
Understanding how the immune system responds to biotherapeutic drugs is essential for predicting their safety and effectiveness. Some patients will develop anti-drug antibodies (ADA) that can change h
DataCite Commons2025-12-19 更新100
Evaluation of the Effect of Hepatic Impairment on the Pharmacokinetics and Metabolism of Oxymorphone Following Administration of Numorphan CR
Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promot
DataCite Commons2025-02-10 更新30
SAE Information 1 in Pharmacokinetics of Anti-epileptic Drugs in Obese Children - Topiramate
SAE Information Page 1 Details Study Description This was a multi-center, prospective, open-label, pharmacokinetic (PK) and safety study of anti-epileptic drugs in obese children age 2 to less than 18
NIAID Data Ecosystem00
The main pharmacokinetic parameters of Compound 1 after intravenous administration at 180/kg Compound 1 in Wistar rats (mean ± S.D., n = 6).
t1/2, half-life; Ke: elimination rate constant; Tmax: time of peak concentration; Cmax: maximum concentration; AUC0–96: area under the curve up to 96 h; AUC0–∞, area under the total concentration-time
NIAID Data Ecosystem40
Multiple comparisons of the pharmacokinetic parameters within each group.
*The difference between the two groups is p<0.05. 1. The Chromogenic substrate assay; 2. ELISA; 3. the total radioisotope assay; 4. the trichloroacetic acid pre-treated total radioisotope assay. The s
NIAID Data Ecosystem20
